81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...

NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...

Just like old wine in a new bottle, an old meme has gotten an analog horror makeover with the SCP-67 kid. The trend has gone viral on TikTok with several versions showing the character with his mouth ...

LMP Capital and Income Fund Inc. is a multi-sector hybrid fund that invests in a fairly diversified portfolio of common stocks, equity REITs, midstream MLPs, and fixed income securities. Recent 3- and ...

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...

SCD seeks total returns with a primary focus on income, investing globally in companies with strong fundamentals and clear market advantages. The fund uses leverage to enhance returns, with interest ...

Sickle cell disease is one of the most common inherited blood disorders worldwide, with a particularly heavy burden in sub-Saharan Africa. Every year, hundreds of thousands of infants are born with ...

This study showed caregivers of children with SCD demonstrated higher scores related to hope than caregivers of children with cancer did. A pilot study involving the experiences of caregivers suggests ...

Sun Pharmaceutical Industries Limited announced top-line results from the phase 2 clinical trial evaluating the safety and efficacy of SCD-044 (a novel, orally bioavailable sphingosine-1- phosphate ...

Sickle cell disease (SCD) altered CD8+ T-cell chromatin architecture, triggering ferroptosis and weakening antitumor immunity. Hydrogen sulfide (H2S) treatment restored chromatin interactions and ...